Lupin Diagnostics achieves 100% NABL accreditation for all greenfield labs
Lupin Diagnostics Limited, a wholly owned subsidiary of global pharmaceutical company Lupin, has announced that it has secured 100% NABL accreditation across all its greenfield laboratories in India. This makes Lupin Diagnostics one of the few diagnostic chains in the country to have all its facilities accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
In a statement released on April 23, 2025, Ravindra Kumar, CEO of Lupin Diagnostics, said, 'This accreditation is a testament to the team's dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics.'
The recognition reflects Lupin Diagnostics' consistent focus on quality, operational efficiency, and patient-centric services. The company has been recognized with several national awards, including the 'Patient-Centric Diagnostic Laboratories Company of the Year' at the IHW 3rd Patients First Award 2024, and 'Pathology Lab of the Year' at the ET Healthcare Awards 2022 and 2024.
Founded in December 2021, Lupin Diagnostics started with a 45,000 sq. ft. National Reference Laboratory in Navi Mumbai and has since grown its footprint across West, South, East, and Central India. Its labs provide over 3,000 types of diagnostic tests, including molecular diagnostics, microbiology, cytology, immunology, and biochemistry.
This milestone marks a significant step in Lupin's broader vision of enhancing healthcare infrastructure in India and promoting accurate, reliable, and accessible diagnostics to every corner of the country.
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
36 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
Indianapolis Star
16 hours ago
- Indianapolis Star
Boost your productivity with an electric standing desk on sale ahead of Labor Day
After a busy summer full of vacations and perhaps a little more flexibility at work, you might feel the itch to get back into a routine this fall. Giving your office a budget-friendly refresh is one way to set yourself up for success and keep you motivated as we usher in a new season. And, with early Labor Day deals popping up just in time for back-to-school season, it is a great chance to revamp your WFH space. If you want to keep your summer activity levels going, switch to a standing desk such as the popular Vivo Electric Standing Desk (which is currently on sale for under $300) and, while you're at it, add a walking pad to the mix, too! Below, we've highlighted the perks about this Amazon deal on the Vivo Electric Standing Desk, plus a few tips for how to save more at Amazon! The Vivo Electric Standing Desk has more than 5,000 Amazon reviews and more than 1,200 five-star ratings, thanks to its durable construction and versatility. This standing desk is available in a standard 63-inch by 32-inch size (plus eight other sizes ranging from as small as 43 x 24 all the way up to 83 x 30). It also comes in a whopping 40 different finishes, so you can choose the style that best fits your office decor. In addition to its size options and good looks, this desk is designed with all-steel construction with a scratch-resistant carbon fiber surface and can withstand up to 176 pounds on its desktop. And it has a powerful motor that can easily adjust the height from 29 inches up to 48.2 inches for when you need to stretch your legs a bit. Adding to its overall convenience, you don't have to readjust the desk every time you use it. Thanks to its built-in memory controller, you can save four different heights and quickly flip between these settings depending on your needs. Original price: $299.99 | Sale price: 254.99 | Savings: $45 Save 15% at Amazon More: Your Labor Day 2025 shopping guide to the best end-of-summer deals Amazon Prime is a paid membership program that offers various benefits primarily focused on shopping and entertainment. Key perks include free shipping on eligible items, access to streaming content such as Prime Video and Amazon Music. Plus there's exclusive deals and discounts available. More: Is an Amazon Prime membership worth it? Here's what you need to know Currently, new members can try a week of Amazon Prime benefits for just $1.99. After the trial, the membership costs $14.99 per month. Amazon Prime for Young Adults (previously Prime for Students) is a new membership that is focused on perks for young adults between the ages of 18 and 24. Join Prime for Young Adults More: Amazon Prime for Young Adults is back! Do you qualify for the discount? Find out here Prime Access: If you receive SNAP, EBT, Medicaid or other qualifying government aid, you can save with a discounted Prime Access membership.
Business Upturn
a day ago
- Business Upturn
KPIT Technologies completes acquisition of Caresoft for $157 million
By Aditya Bhagchandani Published on August 16, 2025, 13:11 IST KPIT Technologies announced on Friday that it has completed the acquisition of Caresoft, finalizing the deal at a revised value of up to USD 157 million. The transaction covers Caresoft Global Technologies, Inc. USA, Caresoft Engineering Services Limited, UK, CAREGLOTECH de RL de CV Mexico, and OXI SRL Italy. The acquisition was first disclosed in May 2025 with an estimated deal size of USD 191 million. However, after negotiations and considering changes in the global business environment, the final consideration was reduced to USD 157 million, which also includes a USD 15 million variable pay component tied to revenue and business synergy milestones. Ahead of the completion, KPIT had infused EURO 28 million and USD 28 million into its UK and US subsidiaries, respectively, to strengthen the capital structure required for the acquisition. Following the satisfaction of all precedent conditions, KPIT Technologies (UK) Limited and KPIT Technologies Inc, USA have paid the initial consideration of USD 51 million to acquire full ownership of the Caresoft entities. This acquisition aligns with KPIT's strategy of strengthening its global presence in automotive engineering and expanding capabilities across the U.S., Europe, and Mexico. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
